爱朋医疗5月12日在互动平台上回复投资者称，公司与美国上市公司脑再生科技没有关系。 ...

脑机接口概念股午后持续走低，爱朋医疗（300753）跌近10%，均普智能跌超7%，荣泰健康 （603579）跌超6%，诚益通（300430）、三博脑科（301293）、翔宇医疗跟跌。 ...

Core Insights - The medical beauty sector experienced a slight increase of 0.53% on May 8, with a total capital outflow of 224.7 million [1] - A total of 43 stocks in the sector rose, while 21 stocks declined [1] Top Gainers - The top ten gainers in the sector included: - Aipeng Medical: +13.1% - Haochen Medical: +9.85% - Guangyunda: +9.8% - ST Jingfeng: +5.01% - ST Biological: +4.98% - Hangzhou Jiebai: +4.34% - Langzi Co.: +4.11% - Hanyu Pharmaceutical: +2.7% - Xinyaqiang: +1.57% - Dezhan Health: +1.29% [1] Top Losers - The stocks with the largest declines included: - Hanshang Group: -9.99% - Lafang Cosmetics: -6.79% - Changshan Pharmaceutical: -5.7% - ST Suwu: -4.84% - Chaohongji: -4.75% [1]

脑机接口概念股盘初冲高，爱朋医疗（300753）涨超15%，荣泰健康（603579）、麒盛科技（603610） 涨停，南京熊猫（600775）、诚益通（300430）跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

Market Overview - The Shanghai Composite Index is at 3305.11 points, below the six-month moving average, with a change of 0.80% [1] - The total trading volume of A-shares is 646.819 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 272 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Zhongcheng Technology: 14.42% deviation, with a price increase of 14.99% [1] - Oulutong: 10.01% deviation, with a price increase of 11.78% [1] - Jiusheng Electric: 9.22% deviation, with a price increase of 19.97% [1] Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Yongdong Co., Sumeida, and Yuhua Tian, which have just crossed the six-month line [1] Additional Stocks with Notable Performance - Other stocks with notable performance include: - Benlang New Materials: 8.45% deviation, with a price increase of 10.35% [1] - Quanzhu Co.: 8.00% deviation, with a price increase of 9.85% [1] - Chuanrun Co.: 7.95% deviation, with a price increase of 10.03% [1]

Group 1 - The A-share brain-computer interface sector experienced an initial rise, with Aipeng Medical increasing by over 8% [1] - Chengyitong, Rongtai Health, and Xiangyu Medical all saw increases of over 5% [1] - Companies such as Dineike and Sanbo Neuroscience also followed the upward trend [1]

Core Insights - Brain-computer interface (BCI) technology enables direct communication between the brain and external devices, revolutionizing human-machine interaction and integrating advanced technologies such as neuroscience, AI, and new materials [2][4] - The global BCI industry is projected to reach $7.63 billion by 2029, indicating significant growth potential [4] - China and the United States are leading in BCI development, with a notable number of companies and products entering clinical stages [6][7] Industry Overview - The BCI industry is characterized by a competitive landscape with active companies in over 40 countries, primarily in the US and China, where the number of companies exceeds 100 [7] - As of early 2024, China holds 55.62% of the global patent technology in BCI, leading all countries [6] - The industry is still in its early stages, with many startups emerging and a significant increase in patent applications and funding events [55] Key Companies - **Qiangnao Technology**: Founded in 2018, it specializes in non-invasive BCI technology and has over 200 core patents, with a goal to help 1 million disabled individuals regain mobility [10][12] - **Brain Tiger Technology**: Established in 2021, it focuses on flexible invasive BCI technology and has made significant breakthroughs in core technologies [13][15] - **Brain Land Technology**: Founded in 2018, it integrates BCI technology with medical big data and AI, holding 147 patents as of April 2025 [20][21] - **Borecon**: Founded in 2021, it has developed high-performance BCI systems and has over 100 patents [24][25] - **Weiling Medical**: Established in 2019, it is focused on BCI technology and has initiated clinical research for implantable BCI systems [28] - **Roulint Technology**: Founded in 2020, it specializes in non-invasive BCI technology for consumer electronics and medical applications, holding 161 patents [33] - **Aipeng Medical**: Established in 2001, it has invested in BCI technology and developed several non-invasive BCI products [36][37] - **Kedou BCI**: Founded in 2016, it focuses on invasive BCI technology and has developed various microelectrodes and related devices [40][41] - **Sanbo Neuroscience**: Established in 2003, it has over 50 patents and is involved in clinical applications of BCI technology for neurological disorders [43] - **Chengyitong**: Founded in 2011, it has developed several non-invasive BCI prototypes and holds 303 patents, covering key areas of BCI technology [46] Technological Insights - BCI technology is categorized into invasive, semi-invasive, and non-invasive types, with a focus on improving accuracy, feedback speed, and safety [50][52] - The majority of BCI product development is currently centered on non-invasive devices due to their higher safety and market acceptance [53] - As of 2024, there are 222 registered medical devices related to BCI in China, with 194 classified as Class II medical devices [53]

二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1400 | 0.0108 | -1396.3 | 0.0096 | | 每股净资产（元） | 5.4 | 5.53 | -2.35 | 5.45 | | 每股公积金(元) | 2.62 | 2.62 | 0 | 2.62 | | 每股未分配利润(元) | 1.37 | 1.57 | -12.74 | 1.50 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.65 | 0.88 | -26.14 | 0.94 | | 净利润(亿元) | -0.18 | 0.01 | -1900 | 0.01 | | 净资产收益率(%) | -2.55 | 0.19 | -1442.11 | 0.18 | 数据四舍五入，查看更多财务数据>> | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | ...

为充分尊重投资者，提升公司与投资者的交流效率和针对性，现就公司本次业绩 说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登 录深圳证券交易所互动易平台（http://irm.cninfo.com.cn）"云访谈"栏目，进入问题 征集专题页面进行提问。公司将在本次业绩说明会上，在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 江苏爱朋医疗科技股份有限公司 关于举行2024年度暨2025年第一季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）已于2025年4月19日在巨潮 资讯网（http://www.cninfo.com.cn）上披露了《2024年年度报告》全文及其摘要，于 2025年4月29日披露了《2025年第一季度报告》。 为了便于投资者更全面地了解公司2024年度及2025年第一季度经营情况，公司定 于2025年5月13日（星期二）16:00-17:00 举行2024年度暨2025年第一季度网上业绩说明 会，本次业绩说明会将通过深圳证券交易所提供的"互 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-020 江苏爱朋医疗科技股份有限公司 关于2025年第一季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）根据《深圳证券交易所创业 板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司 规范运作》《创业板上市公司业务办理指南第2号——定期报告披露相关事宜》《企业 会计准则》等相关法律法规以及公司相关会计政策的规定，基于谨慎性原则，为真实、 准确、客观地反映公司的财务、资产和经营状况，对截止2025年3月31日的合并报表范 围内相关资产计提资产减值准备。现将具体情况公告如下： 一、本次计提资产减值准备情况概述 （二）本次计提资产减值准备的资产范围和总金额 （一）本次计提资产减值准备的原因 根据《企业会计准则》及公司会计政策的相关规定，为公允反映公司各类资产的 价值，公司对合并范围内截止2025年3月31日的各类资产进行全面清查，对各类资产的 可变现性进行充分的评估和分析，认为上述资产中部分资产存在一定的 ...